Delirium is the commonest neuropsychiatric disorder in terminally ill cancer patients as well as one of the most devastating in this population (Folstein et al., 1975; Inouye et al., 1990). Sometimes, it is under-recognized, mis-diagnosed or even inappropriately managed. Results revealed its high association with mortality, however, can be reversed. When the diagnosis occurs, declines in cognition, function, and behavioral control can be also addressed so as to correct underlying conditions and respond to patients’ needs. Opioids and psychoactive medications seemed to be the appropriate treatment of delirium in cancer patients. However, more research is needed to scientifically support not only the diagnosis process but also the most effective therapeutic strategies (Breitbart et al., 1997).